IDRX

IDRx is a clinical-stage biopharmaceutical company developing precision therapies to transform cancer care, focusing on highly potent and selective inhibitors like IDRX-42 and IDRX-73 that target key genetic drivers and drug-resistant mutations in gastrointestinal stromal tumors (GIST).